New Zealand markets closed

Fortress Biotech, Inc. (FBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0000-0.1700 (-7.83%)
At close: 04:00PM EDT
2.0500 +0.05 (+2.50%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1700
Open2.1600
Bid1.9600 x 100
Ask2.0400 x 100
Day's range1.9750 - 2.1697
52-week range1.2400 - 12.7500
Volume311,411
Avg. volume444,885
Market cap36.754M
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)-11.3400
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.00
  • GlobeNewswire

    Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

    Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance

  • GlobeNewswire

    Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

    Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development in autoimmune disease; pivotal trial for Waldenstrom macroglobulinemia (WM) is expected to initiate in the second half of 2024 WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mus

  • GlobeNewswire

    Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

    MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi